VitalHub Selected to Present at Canaccord Genuity’s 41st Annual Growth Conference
TORONTO, Aug. 09, 2021 (GLOBE NEWSWIRE) -- VitalHub Corp. (the “Company” or “VitalHub”) (TSXV: VHI) is pleased to announce it...
News
Intra-Cellular Therapies Reports Second Quarter 2021 Financial Results and Provides Corporate Update
CAPLYTA supplemental new drug applications (sNDAs) for the treatment of bipolar depression are under review by the FDA, with a...
Shockwave Medical Reports Second Quarter 2021 Financial Results
SANTA CLARA, Calif., Aug. 09, 2021 (GLOBE NEWSWIRE) -- Shockwave Medical, Inc. (Nasdaq: SWAV), a pioneer in the development and...
Delcath Systems Secures Up to a $20.0 Million Debt Facility with Avenue Venture Opportunities Fund, L.P.
NEW YORK, Aug. 09, 2021 (GLOBE NEWSWIRE) -- Delcath Systems, Inc. (Nasdaq: DCTH), an interventional oncology company focused on the treatment...
Heat Biologics Announces Groundbreaking for New San Antonio Facility
Groundbreaking ceremony to be streamed liveDURHAM, N.C., Aug. 09, 2021 (GLOBE NEWSWIRE) -- Heat Biologics, Inc. (“Heat”) (NASDAQ: HTBX), a...
Axsome Therapeutics Reports Second Quarter 2021 Financial Results and Provides Business Update
Company to host conference call today at 8:00 AM Eastern NEW YORK, Aug. 09, 2021 (GLOBE NEWSWIRE) -- Axsome Therapeutics,...
FUISZ Announces Patent Issuance for Next Generation Heat Not Burn Device Architecture
Franklin, TN, Aug. 09, 2021 (GLOBE NEWSWIRE) -- Fuisz announces the issuance of US 11,076,642, entitled “Vaporizer for Smoking Cigarettes...
Opthea Expands Global Phase 3 ShORe and COAST Wet AMD Trials of OPT-302 into Canada
MELBOURNE, Australia, Aug. 09, 2021 (GLOBE NEWSWIRE) -- Opthea Limited (ASX:OPT; Nasdaq:OPT), a clinical stage biopharmaceutical company developing novel therapies...
ADMA Biologics Announces Commercial Availability of Expanded Vial Size Offerings for BIVIGAM® and NABI-HB®
ADMA Expands Commercial IG Product Offering with Additional BIVIGAM and NABI-HB Vial Sizes BIVIGAM 100 mL Vial and NABI-HB 1...
Trillium Therapeutics Announces Dosing of First Patient in Phase 1b/2 Study of TTI-622 in Combination With Azacitidine in TP53-Mutated Acute Myeloid Leukemia
CAMBRIDGE, Mass., Aug. 09, 2021 (GLOBE NEWSWIRE) -- Trillium Therapeutics Inc. (NASDAQ/TSX: TRIL), a clinical stage immuno-oncology company developing innovative...
Zynerba Pharmaceuticals Reports Second Quarter 2021 Financial Results and Operational Highlights
On track to initiate RECONNECT, a confirmatory pivotal trial of Zygel™ in patients with FXS, in the third quarter of...
Trevena to Release Second Quarter 2021 Financial Results on August 12th, 2021
Company to host conference call on Thursday, August 12th, 2021 at 8:00 a.m. ETCHESTERBROOK, Pa., Aug. 09, 2021 (GLOBE NEWSWIRE)...
Aravive Announces First Patient Dosed in Phase 1b/2 Clinical Trial of AVB-500 for the Treatment of Pancreatic Adenocarcinoma
Trial to Evaluate AVB-500 as a First-Line Treatment in Combination with Gemcitabine and Nab-Paclitaxel Continues Expansion of AVB-500 in Multiple...
Amryt Virtual Capital Markets Event – September 13, 2021 – 1000-1200 EDT
Amryt Virtual Capital Markets Event - September 13, 2021 – 1000-1200 EDT DUBLIN, Ireland, and Boston MA, August 9, 2021,...
Axsome Therapeutics Announces AXS-05 Achieves Primary and Key Secondary Endpoints in the MERIT Phase 2 Trial in Treatment Resistant Depression
AXS-05 significantly delayed the time to relapse of depression compared to placebo (p=0.002, primary endpoint) AXS-05 significantly prevented relapse of...
Algernon Pharmaceuticals Announces Exclusive Licensing Agreement with Dartmouth College
VANCOUVER, British Columbia, Aug. 09, 2021 (GLOBE NEWSWIRE) -- Algernon Pharmaceuticals Inc. (CSE: AGN) (FRANKFURT: AGW) (OTCQB: AGNPF) (the “Company” or...
BioNTech Announces Second Quarter 2021 Financial Results and Corporate Update
More than one billion doses of BNT162b2 vaccine supplied to more than 100 countries or territories worldwide as of July...
Voyager Therapeutics Transforms Pipeline and Increases Investment in Next-Generation TRACER™ AAV Capsid and Vectorized Antibody Platform Technologies
Proprietary AAV capsids to power second-generation efforts in Huntington’s disease and ALS, pre-clinical programs in spinal muscular atrophy and diseases...
NervGen Pharma and Massachusetts General Hospital Collaborate on Preclinical Studies in Alzheimer’s Disease
Dr. Ksenia Kastanenka to Study NVG-291's Potential to Promote Repair in Alzheimer's Disease ModelsVancouver, British Columbia--(Newsfile Corp. - August 9,...
Halberd Corporation’s VITA-SHIELD-MAX(TM) Immunity Support Product Shipped
Jackson Center, Pennsylvania--(Newsfile Corp. - August 9, 2021) - Halberd Corporation (OTC Pink: HALB) reports Vita-Shield-MaxTM, has been shipped! With...